Search PubMed⌕ Search

Biomedical subjects

K F Tipton

Publications and source records attributed to K F Tipton.

At least 73 records · Page 4Linked to original sources
PubMed1995

Alteration in the glial cell metabolism of glutamate by kainate and N-methyl-D-aspartate.

Incubation of coronal slices of rat brain with neurotoxic concentrations of kainate (300 microM) and N-methyl-D-aspartate (NMDA; 500 microM) for 40 min reduced the activity of the glial enzyme, glutamine synthetase, by 33% and 21%, respectively. The immunoreactivity of the neuronal enzyme, gamma gamma-enolase (neuron-specific enolase), was also decreased, but to a lesser extent than glutamine synthetase. Pre-incubation of the slices with L-methionine-S-sulphoximine (500 microM), an irreversible inhibitor of both glutamine synthetase and gamma-glutamylcysteine synthetase, before addition of either kainate or NMDA produced a supra-additive reduction in the activity of the enzyme in both cases. Neither kainate nor NMDA directly inhibited the activity of glutamine synthetase, but kainate did inhibit gamma-glutamylcysteine synthetase, a rate-limiting enzyme of the gamma-glutamyl cycle, which is responsible for maintaining glutathione levels within cells. Pre-incubation of the slices with L-NG-nitroarginine, a competitive inhibitor of nitric oxide synthase, effectively prevented the NMDA-induced reduction in glutamine synthetase and neuron specific enolase, but did not diminish the kainate-induced decrease in the activity of either enzyme. These results provide evidence that NMDA, as well as kainate, indirectly affects the activity of glutamine synthetase in brain slices, yet does so by a different mechanism from kainate. The results are discussed in terms of the possible mode of action of each toxin in inhibiting the glial cell metabolism of glutamate.

Animals↗
PubMed1995

The influence of enzyme concentration on the encapsulation of glutamate dehydrogenase and alcohol dehydrogenase in red blood cells.

Glutamate dehydrogenase (GDH) and alcohol dehydrogenase (ADH) have been encapsulated in sheep and human red blood cells (RBCs) by a hypotonic dialysis/isotonic resealing procedure. At a fixed enzyme level in the dialysis bag (100 units/ml of RBCs), a significant encapsulation yield was observed for ADH, both in human (17.2%) and sheep (47.9%) RBCs, whereas a very low entrapment of GDH was achieved (1-3%) in either species. Carrier cell recovery was 61-65% in humans and 30-34% in sheep. Because of the aggregation of GDH to large polymers at protein levels above 1 mg/ml, the yield of encapsulation and the specific activity in human carrier RBCs were compared at different enzyme concentrations. While entrapment was not affected by differences in ADH up to 13,000 units/ml of RBCs (38 mg/ml), the yield of GDH encapsulation significantly decreased as the enzyme level increased up to 750 units/ml of RBCs (15 mg/ml), thus demonstrating the importance of protein concentration in the encapsulation process for those enzymes that tend to aggregate.

Alcohol Dehydrogenase↗
PubMed1994

Fasciculin inhibition of acetylcholinesterase is prevented by chemical modification of the enzyme at a peripheral site.

Fasciculin 2 (FAS) is a 61 amino acid peptide present in Dendroaspis angusticeps snake venom, with a selective and potent inhibitory activity towards acetylcholinesterase (AChE). The specific interaction of FAS with peripheral sites present in Electrophorus electricus AChE (Ki = 0.04 nM FAS) was investigated by chemical modification with N,N-dimethyl-2-phenylaziridinium (DPA) in the presence of active or peripheral anionic site protective agents. An enzyme was obtained that compared to the native AChE is 10(6)-times less sensitive to FAS, is fully inhibited by edrophonium and tacrine, and is 25-170-times less sensitive to several peripheral site ligands. Characterization of catalytic functions showed that Km for acetylthiocholine was 4-fold lower in the DPA-modified enzyme, whereas Km for phenylacetate remained the same. Values for Kcat determined with both substrates were unchanged. Diminished catalytic efficiency reflects that hydrolysis and/or supply of cationic substrates to the active site was affected by DPA reaction at a peripheral site. Previous data implicate Trp-279 (Torpedo AChE sequence numbering) as the residue actually involved in DPA modification. Our results strongly support FAS binding to an AChE peripheral site which partially overlaps the site of other peripheral site ligands including acetylthiocholine.

Acetylcholinesterase↗
PubMed1994

Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase.

A series of analogues of the anticonvulsant drug milacemide (2-(n-pentylamino)-acetamide; Compound I) has been synthesized: 2-(benzylamino)acetamide (Compound II), 2-(phenethylamino)acetamide (Compound III), 2-(2-indol-3-yl)-ethylamino acetamide (Compound IV), 2-(2-(5-methoxyindol-3-yl)ethylamino)-acetamide (Compound V), 2-(2(4-chlorobenzamido)-ethylamino)acetamide (Compound VI), 2-(2-benzamidoethylamino)-acetamide (Compound VII) and 2-(4-(3-chlorobenzyloxy)phenethylamino)acetamide (Compound VIII). These compounds involve retention of the aminoacetamide portion of milacemide but replacement of the pentyl moiety with aromatic residues present in the structures of substrates and inhibitors of the monoamine oxidases. All the compounds tested were substrates for ox liver monoamine oxidase-B (MAO-B), producing an aldehyde that could act as a substrate for ox liver aldehyde dehydrogenase and H2O2 as a result of oxidative cleavage which also released glycinamide, although their Michaelis-Menten parameters differed markedly. None showed detectable activity as substrates for rat liver monoamine oxidase-A (MAO-A). Inhibition of the MAO-B by all the compounds except Compounds VIII and IV showed marked time dependence and was at least partly irreversible. There was no apparent change in the inhibition of MAO-A during enzyme-inhibitor preincubation at 37 degrees for 60 min. Compound VIII was a potent reversible inhibitor of both MAO-A and MAO-B (Ki = 2.8 +/- 0.1 and 4.1 +/- 0.8 microM), respectively. Comparison of the inhibitory potencies and the specificity constants of the series of compounds as substrates for MAO-B revealed no simple correlations with their anticonvulsant activities, as measured by their ability to prevent bicuculline-induced convulsions and death in the mouse. These results suggest that neither inhibition of MAO nor oxidative cleavage by this enzyme to yield glycinamide plays the major role in the anticonvulsant action of these compounds.

Acetamides↗
PubMed1994

Monoamine oxidase inhibitory effects of some 4-aminophenethylamine derivatives.

The in vitro and ex vivo monoamine oxidase (MAO) inhibitory effects of (+/-)4-dimethylamino-alpha-methyl-phenethylamine (4-DMAA) and (+/-)4-methylamino-alpha-methyl-phenethylamine (4-MAA) were reassessed, in comparison with the previously unstudied achiral parent compound, 4-dimethyl-aminophenethylamine (4-DMAPEA) and with a salt of 4-DMAA enriched in the levo isomer, ("-")-4-DMAA, using amiflamine [S-(+)-4-dimethylamino-alpha,2-dimethylphenethylamine] as positive control. The in vitro studies confirmed that 4-amino-alpha-methylphenethylamine derivatives are highly selective and reversible MAO-A inhibitors. Furthermore, ("-")-4DMAA was less active than the racemic mixture. The side chain-unsubstituted compound, 4-DMAPEA, proved to be a nonselective and reversible MAO inhibitor. The ex vivo results, in which catecholamines, serotonin (5-HT) and their metabolites were measured in two brain regions after i.p. administration, confirmed the results obtained in vitro. These results are consistent with the suggestion that the 4-amino group contributes to MAO inhibitory effects of alpha-methyl-phenethylamines, and show that the presence and orientation of an alpha-methyl side chain substituent may be important when determining the potency and selectivity of these compounds. All compounds tested could be quantified by HPLC with electrochemical detection.

Animals↗
PubMed1994

The interactions of milacemide with monoamine oxidase.

The interactions of the anticonvulsant drug milacemide (2-n-pentylaminoacetamide) with rat liver mitochondrial monoamine oxidases-A and -B have been studied. The compound acts as a substrate for the B-form of the enzyme, with an apparent Km value of 49 +/- 4.7 microM and a Vmax value of 1.1 +/- 0.2 nmol/min/mg. It is also a time-dependent irreversible inhibitor of that enzyme. Any activity of monoamine oxidase-A towards this substrate was too low to allow accurate determinations to be made by either luminometric determination of H2O2 formation or spectrophotometric coupling of aldehyde formation to NAD+ reduction in the presence of aldehyde dehydrogenase. Milacemide was a reversible competitive inhibitor towards monoamine oxidase-A. The inhibitor constant (Ki) was 115 +/- 35 microM indicating a higher affinity than that towards monoamine oxidase-B, which was also competitively inhibited in the absence of enzyme-inhibitor preincubation (Ki = 331 +/- 185 microM). Determination of the formation of H2O2 and the aldehyde product of the oxidative cleavage of milacemide by purified monoamine oxidase-B from ox liver indicated that cleavage resulted solely in the formation of pentanal and glycinamide. There was no evidence for alternative cleavage to pentylamine and oxamaldehyde.

Acetamides↗
PubMed1994

Inhibition of monoamine oxidase by clorgyline analogues.

N-Methyl-N-propargyl-3-(4-phenoxy)phenoxypropylamine, an analogue of the MAO-A-selective irreversible inhibitor clorgyline in which the 2,4-dichloro- substitution in clorgyline was replaced by a 2-H atom and a 4-phenoxy group, has been synthesised and assessed as an inhibitor of monoamine oxidase (MAO). This compound proved to be a time-dependent irreversible inhibitor of both MAO-A and -B. However, unlike clorgyline, it was selective towards MAO-B, both in its initial, non-covalent, binding to the enzyme and as an irreversible inhibitor. In order to assess the influence of side-chain length on inhibitory potency, analogues were synthesised in which the side-chain was reduced to 2 CH2 units (N-methyl-N-propargyl-2- (4-phenoxy)phenoxyethylamine) or increased to 4 CH2 units (N-methyl-N-propargyl-4-(4- phenoxy)phenoxybutylamine). Both these compounds were also time-dependent irreversible inhibitors with selectivity towards MAO-B. In the case of the initial, non-covalent, inhibition all these compounds were competitive inhibitors of MAO-A, with respect to the amine substrate, and the affinity for inhibitor binding increased with carbon chain length. In contrast the compounds were all mixed inhibitors of MAO-B. The competitive element of this inhibition (measured by Kis) was similar for the 2 and 3 carbon-chain compounds but decreased markedly when the chain-length was increased to 4 carbons. The uncompetitive inhibition (measured by Kii) decreased as the carbon chain-length was increased from 2 to 3, but there was no significant further change when the length was increased to 4 carbons. The time-dependent irreversible inhibition (measured as the IC50 values after 60 min enzyme-inhibitor preincubation) showed that the potency towards MAO-A increased when the side-chain length was increased from 2 to 3 carbons but that there was no significant difference between the 3 and 4 carbon-chain compounds. In the case of MAO-B inhibition, the 2 and 3 carbon-chain compounds had similar inhibitory potencies but this increased substantially when the chain length was increased to 4 carbons. The significance of the inhibitory behaviour of these compounds is discussed in terms of the structure-activity relationships of mechanism-based irreversible MAO inhibitors.

Chemical Phenomena↗
PubMed1994

Estimation of monoamine oxidase concentrations in soluble and membrane-bound preparations by inhibitor binding.

A modification of the [3H]-pargyline labelling technique is presented for determining the active-site concentration of monoamine oxidase in soluble preparations. Kinetic considerations show that the rate of reaction of MAO-A with low concentrations of free pargyline will be very much slower than that of MAO-B. Failure to use adequate reaction times for the concentration of pargyline added can lead to gross underestimation of the quantity of MAO-A present.

Animals↗
PubMed1994

The effects of ethanol on rat brain monoamine oxidase activities.

In contrast to the reported behaviour of human platelet MAO-B, chronic ethanol feeding does not significantly affect the sensitivities of either MAO-A or -B from rat brain to inhibition by ethanol in vitro. The thermal stabilities of rat brain MAO-A and -B are not significantly affected by chronic ethanol feeding.

Animals↗
PubMed1994

What is it that l-deprenyl (selegiline) might do?

There have been many claims that l-deprenyl may have distinct properties in slowing and perhaps even in reversing the progression of Parkinson's disease and other neurodegenerative conditions. This article will consider the paucity of evidence that such is the case in humans and the more detailed results from studies with experimental animals indicating that deprenyl may indeed express such a property. The conflicting data on its mechanism of action are considered and the concept that it may function to enhance neuronal fitness is advanced as an alternative to the neuroprotection and neurorescue hypotheses. Possible lines of experimental development that would help resolve some of the many unanswered questions regarding l-deprenyl function are outlined.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗
PubMed1993

A discontinuous luminometric assay for monoamine oxidase.

A simple, sensitive and convenient discontinuous luminometric assay for monoamine oxidase (MAO) is described. It is based on measurement of the light production from the peroxidase-catalysed chemiluminescent oxidation of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) by the hydrogen peroxide produced in the MAO reaction. The procedure is suitable for use with a wide range of MAO substrates, although 5-hydroxytryptamine, adrenaline and noradrenaline are too readily oxidized by hydrogen peroxide to be used. A particular advantage of this procedure is that it is applicable to the oxidation of substrates which do not yield products, such as an aldehyde or free ammonia, which form the basis of several alternative substrate-independent assay procedures. The application of the procedure to assay the oxidation of benzylamine, tyramine and 2-n-pentylaminoacetamide (milacemide) by a crude mitochondrial preparation from rat liver and purified ox liver MAO-B is demonstrated.

Animals↗